New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
08:09 EDTBIIB, RGLSRegulus Therapeutics and Biogen enter into new collaboration agreement
Regulus Therapeutics (RGLS) announced that it has entered into a new collaboration agreement with Biogen (BIIB) to expand its research focused on identifying microRNAs as biomarkers for multiple sclerosis, or MS, under its Regulus microMarkers division. The new research will focus on profiling a large number of whole blood samples from a cohort of MS patients who have been treated with a Biogen MS therapy to identify potential microRNA signatures. Regulus will receive $2M upfront and is eligible for future payments upon achievement of certain milestones related to the identification of potential microRNA signatures.
News For RGLS;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
11:08 EDTBIIBBiogen to add PML info on Tecfidera label after patient dies
Subscribe for More Information
11:04 EDTBIIBFDA says Biogen adding PML information on Tecfidera label
November 24, 2014
10:00 EDTRGLSOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:59 EDTBIIBBiogen resumed with an Outperform at Leerink
Subscribe for More Information
06:00 EDTRGLSRegulus Therapeutics initiated with a Buy at Deutsche Bank
Subscribe for More Information
November 19, 2014
08:59 EDTRGLSRegulus Therapeutics data positive, says Wedbush
Subscribe for More Information
07:52 EDTBIIBInforma Business Information to hold a conference
Subscribe for More Information
07:21 EDTBIIBBiogen price target lowered to $400 from $425 at Credit Suisse
Credit Suisse lowered Biogen's price target to $400 from $425 based on Gilenya PPMS risk but retains its Outperform rating based on the quality of earnings growth and pipeline.
November 16, 2014
14:44 EDTRGLSRegulus, Sanofi present new data enhancing the preclinical profile of RG-012
Subscribe for More Information
November 13, 2014
10:42 EDTBIIBSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
10:27 EDTRGLSHigh option volume stocks
Subscribe for More Information
07:54 EDTRGLSRegulus Therapeutics 2M share Block Trade priced at $18.25
Morgan Stanley acted as sole book running manager for the offering.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use